Prof

Prof. Dr. Claus R. Bartram
Director Institute of Human Genetics, Heidelberg
Dean, Medical Faculty Heidelberg
Institute of Human Genetics Im Neuenheimer Feld 366 69120 Heidelberg 06221-565151 (phone) 06221-565155 (fax) [email protected] SCIENTIFIC VITA
Graduation (Medicine) and M.D. degree (summa cum laude), University of Hamburg 1979 - 1982 Specialization in Pediatrics at the University Childrens’ Hospital in Düsseldorf 1982 - 1983 DFG Scholarship at the Erasmus University Rotterdam, 1984 - 1985 Specialization in Pediatrics at the University Childrens’ Hospital in Ulm Board Certification in Pediatrics (1988) Habilitation (Pediatrics) at the University of Ulm Associate Professor and Head of the Section Molecular Biology, Department of Appointed to the Chair of Clinical Molecular Biology at the University of Ulm Board Certification in Human Genetics (1995). Appointed to the Chair of Human Genetics at the University of Heidelberg Director of the Institute of Human Genetics, University of Heidelberg (01.10.1995) Appointmented to the Chair of Clinical Genetics at the Erasmus University in Science Award from the Kind-Philipp-Foundation for Leukemia Research (1984); Science Award from the City of Ulm (1987); The Artur Pappenheim Award from the German Society for Hematology and Oncology (1989); Science Award from the Johann Georg Zimmermann Foundation for Cancer Research (1990); Mildred Scheel Memorial Lecture from the German Cancer Aid (1992); Robert Pfleger Award from the Dr. Robert Pfleger Foundation (1992); The Wilhelm Warner Foundation Science Award (1993); Merckle Award for Research from the University of Ulm (1994); Redlich Memorial Lectureship in Hematology, Visiting Professor at the Cedars-Sinai Medical Center, UCLA (1995); Lingen Foundation Science Award (1996); German Cancer Aid Award (2000) FIELDS OF INTEREST
Cancer genetics, molecular characterization of hematopoietic neoplasias, minimal residual disease, hereditary cancer disposition. SELECTED PUBLICATIONS

Wirtenberger M, Frank B, Hemminki K, Klaes R, Schmutzler RK, Wappenschmidt B, Meindl A,
Kiechle M, Arnold N, Weber BH, Niederacher D, Bartram CR, Burwinkel B (2006). Interaction of
Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 27, 1655-
1660
Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Welte K, Ludwig WD, Bartram CR,
Zanger UM, Eichelbaum M, Schrappe M, Schwab M (2005). Thiopurine methyltransferase (TPMT)
genotype is an independent modulator of early treatment response to 6-mercaptopurine in
childhood acute lymphoblastic leukaemia. JAMA 293, 1485-1489
Cario G, Stanulla M, Fine BM, Teuffel O, v Neuhoff N, Schrauder A, Flohr T, Schafer BW, Bartram
CR, Welte K, Schlegelberger B, Schrappe M (2005). Distinct gene expression profiles determine
molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105, 821-826
Willemse MJ, Seriu T, d'Aniello E, Hop WCJ, Panzer-Grumayer ER, Biondi A, Schrappe M, Kamps
WA, Masera G, Gadner H, Riehm H, Bartram CR, van Dongen JJM (2002). Detection of minimal
residual disease identifies differences in treatment response between T-ALL and precursor-B-ALL.
Blood 99, 4386-4393
Gleißner B, Gokbuget N, Bartram CR, Janssen LAJ, Rieder H, Janssen JWG, Fonatsch C, Heyll A,
Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E (2002). Leading prognostic
relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a
prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction
analysis. Blood 99, 1536-1543
Tsukasaki K, Krebs J, Nagai K, Tomonaga M, Koeffler HP, Bartram CR, Jauch A (2001).
Comparative genomic hybridization (CGH) analysis of adult T-cell leukemia/lymphoma (ATL):
correlation with clinical course. Blood 97, 3875-3881
Janssen JWG, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl
WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E (2000). Concurrent activation of a novel
putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with
t(11;14)(q13;q32). Blood 95, 2691-2698, 2000.
Kamatsu N, Takeuchi S, Ikezoe T, Tasaka T, Hatta Y, Machida H, Williamson IK, Bartram CR,
Koeffler HP, Taguchi H (2000). Mutations of the E2F4 gene in hematological malignancies having
microsatellite instability. Blood 95, 1509-1510
Nakao M, Janssen JW, Flohr T, Bartram CR (2000). Rapid and reliable quantification of minimal
residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell
receptor loci by LightCycler technology. Cancer Res 60, 3281-3289
Van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz
F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn
MAC, Cazzaniga G, Hettinger K, van der Does-van der Berg A, Hop WCJ, Riehm H, Bartram CR
(1998). Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood.
Lancet 352, 1731-1738

Source: http://www.translational-oncology.de/fileadmin/templates/pdf/bartram.pdf

mqio.files.wordpress.com

Alendronate sodium+cholecalciferolAlfuzosin hydrochlorideAlmitrine bismesylate and raubasine Per tablet; Almitrine bismesylate tissue plasminogen activatorAluminum and magnesium hydroxide Per tablet; Aluminum hydroxide Aluminum and magnesium hydroxide Per 5 mL; Aluminum hydroxide 225 mg, magnesium hydroxide 200 mg. 180 mL178 mg, magnesium hydroxide 233 mg and simethicone 30 mg1.9225 g, l-leu

bverwg.de

BUNDESVERWALTUNGSGERICHT IM NAMEN DES VOLKES hat der 5. Senat des Bundesverwaltungsgerichts auf die mündliche Verhandlung vom 8. November 2012 durch den Vorsitzenden Richter am Bundesverwaltungsgericht Vormeier, die Richterin am Bundesverwaltungsgericht Stengelhofen und die Richter am Bundesverwaltungsgericht Dr. Störmer, Dr. Häußler und Dr. Fleuß für Recht erkannt: Die Revision de

Copyright © 2012-2014 Medical Theses